Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Outcome of Infants Younger Than 1 Year With Acute Lymphoblastic Leukemia Treated With the Interfant-06 Protocol: Results From an International Phase III Randomized Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Cancer Risks Associated With Germline PALB2 Pathogenic Variants: An International Study of 524 Families

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiovascular Risk Factors and Disease After Male Germ Cell Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Response to: Patient-centred medical education: A proposed definition

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Associations between pretherapeutic body mass index, outcome, and cytogenetic abnormalities in pediatric acute myeloid leukemia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Rob Pieters
  • Paola De Lorenzo
  • Philip Ancliffe
  • Luis Alberto Aversa
  • Benoit Brethon
  • Andrea Biondi
  • Myriam Campbell
  • Gabriele Escherich
  • Alina Ferster
  • Rebecca A Gardner
  • Rishi Sury Kotecha
  • Birgitte Lausen
  • Chi Kong Li
  • Franco Locatelli
  • Andishe Attarbaschi
  • Christina Peters
  • Jeffrey E Rubnitz
  • Lewis B Silverman
  • Jan Stary
  • Tomasz Szczepanski
  • Ajay Vora
  • Martin Schrappe
  • Maria Grazia Valsecchi
Vis graf over relationer

PURPOSE: Infant acute lymphoblastic leukemia (ALL) is characterized by KMT2A (MLL) gene rearrangements and coexpression of myeloid markers. The Interfant-06 study, comprising 18 national and international study groups, tested whether myeloid-style consolidation chemotherapy is superior to lymphoid style, the role of stem-cell transplantation (SCT), and which factors had independent prognostic value.

MATERIALS AND METHODS: Three risk groups were defined: low risk (LR): KMT2A germline; high risk (HR): KMT2A-rearranged and older than 6 months with WBC count 300 × 109/L or more or a poor prednisone response; and medium risk (MR): all other KMT2A-rearranged cases. Patients in the MR and HR groups were randomly assigned to receive the lymphoid course low-dose cytosine arabinoside [araC], 6-mercaptopurine, cyclophosphamide (IB) or experimental myeloid courses, namely araC, daunorubicin, etoposide (ADE) and mitoxantrone, araC, etoposide (MAE).

RESULTS: A total of 651 infants were included, with 6-year event-free survival (EFS) and overall survival of 46.1% (SE, 2.1) and 58.2% (SE, 2.0). In West European/North American groups, 6-year EFS and overall survival were 49.4% (SE, 2.5) and 62.1% (SE, 2.4), which were 10% to 12% higher than in other countries. The 6-year probability of disease-free survival was comparable for the randomized arms (ADE+MAE 39.3% [SE 4.0; n = 169] v IB 36.8% [SE, 3.9; n = 161]; log-rank P = .47). The 6-year EFS rate of patients in the HR group was 20.9% (SE, 3.4) with the intention to undergo SCT; only 46% of them received SCT, because many had early events. KMT2A rearrangement was the strongest prognostic factor for EFS, followed by age, WBC count, and prednisone response.

CONCLUSION: Early intensification with postinduction myeloid-type chemotherapy courses did not significantly improve outcome for infant ALL compared with the lymphoid-type course IB. Outcome for infant ALL in Interfant-06 did not improve compared with that in Interfant-99.

OriginalsprogEngelsk
TidsskriftJournal of clinical oncology : official journal of the American Society of Clinical Oncology
Vol/bind37
Udgave nummer25
Sider (fra-til)2246-2256
Antal sider11
ISSN0732-183X
DOI
StatusUdgivet - 2019

ID: 59096724